Cidara (CDTX) Q2 Cash Surges 163%

Cidara Therapeutics (NASDAQ:CDTX), a biotechnology company focused on the development of innovative therapies for infectious diseases and oncology, released its second-quarter 2025 earnings on August 7, 2025. The company reported GAAP earnings per share of $1.65. This result was significantly better than the analyst expectation of a $1.94 loss (GAAP EPS). There was no revenue (GAAP), aligning with forecasts due to the wind-down of a key collaboration earlier in the year. The quarter showcased major clinical advances for its flagship drug candidate and strong financial de-risking through a major equity raise. Overall, the period marked a pivotal step forward for Cidara, though it remains a pre-commercial biotech with no revenue-generating products. Source: Analyst estimates for the quarter provided by FactSet. Cidara Therapeutics is a clinical-stage biotechnology company developing drugs for infectious diseases and cancer. Its flagship program is CD388, a drug-Fc conjugate (DFC) designed to prevent influenza. DFCs are engineered molecules that combine targeted drug activity with extended lifespans in the body, aiming to offer protection for at-risk populations.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool